Szalay Aladar has filed an amended Schedule 13G, revealing an increase in his beneficial ownership of Genelux Corp. This update is significant as it shows Aladar now holds 6.2% of the company’s common stock, which could impact investor sentiment and the company's market dynamics.

Genelux Corp operates within the pharmaceutical preparations industry, focusing on innovative treatments and therapies. The company is incorporated in Delaware and is headquartered in Westlake Village, California. Its shares are traded publicly, and the recent filing indicates a strategic move by Aladar to strengthen his position in the company.

According to the filing dated November 4, 2026, Aladar Szalay reported beneficial ownership of 2,834,465 shares of Genelux Corp. This includes shares held by various trusts for which he has voting and dispositive power. Specifically, he holds 599,821 shares through The Szalay 2010 Retained Annuity Trust and 550,000 shares through The Szalay 2010 Children's Trust. Additionally, he shares voting power over 1,679,644 shares held by the Szalay Trust dated August 30, 2021.

"This filing shows Aladar Szalay's continued commitment to Genelux Corp, reflecting confidence in the company's future prospects," the filing states.

The update may have implications for Genelux's market strategy and could influence how other investors perceive the company. As a significant shareholder, Szalay's actions may affect the company's governance and operational decisions.

Looking ahead, it remains to be seen how Genelux Corp will respond to this increased ownership and whether further filings will provide additional insights into Szalay's investment strategy. The filing does not specify what actions may follow this update.